On 3 January the Xihu District district committee and government held the 2025 science and technology innovation conference at the Xihu District Cultural and Sports Centre, bringing together academics, district leadership, technology companies and investors. For the second consecutive year the district made innovation the subject of its first meeting of the year.
At the conference Westlake Pharmaceuticals was named a “2024 outstanding innovation and entrepreneurship team”.
In 2024 the district set itself four tasks — science, technology, innovation and newness — with notable results. Five annual lists were released at the conference: five teams as outstanding innovation and entrepreneurship teams; twelve AI models as breakthrough results of the year; ten companies as key innovation leaders; 22 companies as frontier innovation emerging enterprises; and six platforms as new high-level platforms.
Technology transfer is the critical link in innovation and its value keeps rising. Westlake Pharmaceuticals, a technology transfer company of Westlake University, is a deep practice in combining the resources of scientists, entrepreneurs and investors, and is growing quickly with policy support.
2024 was the company’s fourth year. Its first original drug, Mprosevir®, was in the marketing application stage, and a second, WPV02, had been approved to enter Phase 1 trials. The oncology pipeline was progressing, with two programmes reaching staged breakthroughs.
A district science bureau official said the recognised organisations set a benchmark with distinctive experience, encouraging universities, institutes and companies to innovate and leading a new trend in technology transfer.
The honour recognises past work and encourages the team. In 2025 Westlake Pharmaceuticals will keep focusing on research and on the difficult problems, contributing to new productive forces.